EZH2 and pancreatic neoplasm: Previous studies have demonstrated that DUXAP10 plays a carcinogenic role in non-small cell lung cancer [15], colorectal cancer [16], and gastric cancer [17] by binding LSD1; DUXAP10 promotes tumor progression in pancreatic cancer [18] and esophageal squamous cell carcinoma [19] by binding EZH2; DUXAP10 promotes cell proliferation by inhibiting PI3K/Akt/mTOR signaling pathway in bladder cancer [20].